The effect of intravenous magnesium sulfate as a complementary therapy to COPD
Phase 3
Recruiting
- Conditions
- Chronic obstructive pulmonary disease.j44
- Registration Number
- IRCT20150315021480N8
- Lead Sponsor
- Vice chancellor for research of Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
All patients with chronic pulmonary obstruction with moderate severity.
Exclusion Criteria
Patients who have the need for intubation.
Patients who have a history of heart disease
Patients who have a low level of consciousness
Patients who received intravenous magnesium sulfate within the last 24 hours
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of breaths. Timepoint: Counting the number of breaths at the beginning of the study (before the intervention) and 45 minutes and 6 hours after starting magnesium sulfate. Method of measurement: We count the breath per one minute.
- Secondary Outcome Measures
Name Time Method Blood pressure. Timepoint: before intervention and 45 minutes and 6 hours after intervention. Method of measurement: We get blood pressure using a manometer portable .